THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 ("MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.
Mereo BioPharma Group plc
("Mereo" or the "Company")
Mereo Biopharma and Oncomed Pharmaceuticals Joint Conference Call
To be effected by an all-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019
Deal broadens asset and shareholder base and extends Enlarged Group cash runway
Enlarged Group expects to launch new NASDAQ-Listed ADR programme
Conference call and webcast today with Dr Denise Scots-Knight and Dr John Lewicki, 8:30 a.m. ET / 1:30 p.m. GMT